Drug Found to Fight Marfan (Australia)
This article was originally published in PharmAsia News
Researchers at the Baker Heart Research Institute in Melbourne, Australia, have discovered an existing drug that may be helpful for treating Marfan syndrome. The drug, called perindopril, works to reduce the fragility of the aorta. Aortic rupture is the leading cause of death in people with Marfan, which is a genetic condition that causes imperfections in the connective tissues of the body's skeletal, ocular, and cardiovascular systems. Up until now, most patients with Marfan had to take beta-blockers to slow their heart rate in an attempt to prevent stress on the aorta. But these drugs do nothing to strengthen the aorta and Marfan sufferers often have to undergo multiple heart surgeries, which are both expensive and risky. Scientists say using perindopril will cut down on the need for those surgeries, increasing the quality of life for those with the disease. (Click here for more
You may also be interested in...
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.